Louis Staudt, M.D., Ph.D., a pioneer in gene expression profiling at the National Cancer Institute (NCI), will deliver the next Flexner Discovery Lecture on Thursday, March 19.
His lecture, entitled “Therapy of Lymphoma Inspired by Functional and Structural Genomics,” begins at 4 p.m. in 208 Light Hall. It is sponsored by the Vanderbilt-Ingram Cancer Center.
Staudt is co-chief of the Lymphoid Malignancies Branch at the NCI and director of the NCI Center for Cancer Genomics. The center oversees several large-scale managed programs studying the genomic aberrations in cancer.
He pioneered the use of gene expression profiling to discover molecularly and clinically distinct cancer subtypes and to predict response to therapy. He defined molecular subtypes of lymphoma that were previously unrecognized.
The Staudt laboratory uses genomic approaches to establish a molecular diagnosis of lymphoid malignancies and to discover new targets for therapy in these diseases.
He has received numerous awards for his research, including the 2009 Dameshek Prize from the American Society of Hematology for outstanding contributions to hematology, and election to the National Academy of Sciences in 2013.
For a complete schedule of the Flexner Discovery Lecture series and archived video of previous lectures, go to www.mc.vanderbilt.edu/discoveryseries.
